Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
NeOnc Technologies Holdings, Inc. ( (NTHI) ) has issued an update.
NeOnc reported its second-quarter 2026 results on August 10, 2026, alongside clinical and regulatory milestones for its NEO100 and NEO212 programs, underscoring a strategic focus on advancing central nervous system cancer treatments. The company completed topline analysis of its Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma and plans to present the data to investors on August 12, 2026, marking a key clinical inflection point.
In June 2026, NeOnc secured UAE IND approvals for both NEO100 and NEO212, broadening its international trial footprint and complementing existing U.S. development, while July brought FDA feedback supporting continued progress of NEO212 and the appointment of Nasim Shomali to the board. Financially, second-quarter 2026 results showed lower general and administrative costs, sharply higher research and development spending tied to trial expansion, a wider net loss heavily influenced by noncash stock-based compensation, and limited cash offset by access to multiple capital facilities, highlighting both an aggressive investment posture and ongoing funding needs for stakeholders.
The most recent analyst rating on (NTHI) stock is a Buy
with a $15.00 price target.
To see the full list of analyst forecasts on NeOnc Technologies Holdings, Inc. stock,
see the NTHI Stock Forecast page.
Spark’s Take on NTHI Stock
According to Spark, TipRanks’ AI Analyst, NTHI is a Neutral.
The score is held down primarily by very weak financial performance (no TTM revenue, large losses, negative equity, and significant cash burn). Technicals also remain bearish with price below key moving averages, partially offset by oversold signals. Offsetting factors are positive corporate/regulatory developments and recent financing that may extend the company’s ability to execute on its pipeline.
To see Spark’s full report on NTHI stock,
click here.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on central nervous system cancers, developing therapies that overcome the blood-brain barrier using its NEO drug development platform. Its lead candidates include NEO100, in multiple Phase 1 and Phase 2 trials with FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations, and NEO212, which has completed Phase 1 and is progressing toward Phase 2.
Average Trading Volume: 77,862
Technical Sentiment Signal: Sell
Current Market Cap: $90.76M
For an in-depth examination of NTHI stock, go to TipRanks’ Overview page.